---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-006099"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:28:59.889559+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Puma Biotechnology reports Q4 GAAP net income of $12.3M; guides Q1 2024 net loss of $10-12M

## Summary
- Product revenue net Q4 $53.2M (flat YoY); full year $203.1M, up from $200.0M.
- GAAP net income Q4 $12.3M ($0.26/diluted) vs net loss $5.6M in Q4 2022.
- Non-GAAP adjusted net income Q4 $14.8M ($0.31/share) vs adjusted net loss $3.0M.
- Cash and marketable securities $96.0M at Dec 31, 2023, up from $81.1M a year ago.
- Guidance: Q1 2024 net product revenue $38-40M, net loss $10-12M; FY2024 net income $12-15M.

## SEC filing metadata
- accession: 0001437749-24-006099
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774924006099/0001437749-24-006099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774924006099/pbyi20240227_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-006099
- JSON: https://secwatch.observer/filing/0001437749-24-006099.json
- Plain text: https://secwatch.observer/filing/0001437749-24-006099.txt

## Key facts
- Earnings Releases
  PUMA BIOTECHNOLOGY, INC. reported financial results for fourth quarter and year ended December 31, 2023.
  - Period: fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: On February 29, 2024, Puma Biotechnology, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000143774924006099/0001437749-24-006099-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.